<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="76517">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02109445</url>
  </required_header>
  <id_info>
    <org_study_id>A8641019</org_study_id>
    <secondary_id>2013-005574-21</secondary_id>
    <nct_id>NCT02109445</nct_id>
  </id_info>
  <brief_title>Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies</brief_title>
  <official_title>Phase 1/2 Study Of Pf-03084014 In Combination With Gemcitabine And Nab-paclitaxel In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academic GI Cancer Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study consists of a Phase 1b portion aimed to determine the maximum tolerated dose and
      the safety profile of PF-03084014 in combination with gemcitabine and nab-paclitaxel
      followed by a Phase 2 portion to evaluate the efficacy of the triple combination in terms of
      overall survival in patients with metastatic pancreatic ductal adenocarcinoma not previously
      treated with anticancer therapies.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated on 24JUN15 due to change in strategy of PF-03084014 development.No
    safety/efficacy concerns were behind the reason of trial termination
  </why_stopped>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Dose-limiting toxicities (DLT) - Phase 1</measure>
    <time_frame>From Cycle 1 Day 1 up to Cycle 1 Day 28.</time_frame>
    <description>First cycle dose limiting toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS) - Phase 2</measure>
    <time_frame>From the date of randomization, every 3 months until death for 30 months.</time_frame>
    <description>Overall survival is the difference in days between the date of death and the date of randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR) - Phase 1 and 2</measure>
    <time_frame>Baseline, on treatment every 8 weeks from the first occurrence of objective response, until disease progression or death, up to 12 months</time_frame>
    <description>Only for subjects who achieved a CR or PR as per RECIST 1.1. DR is the time in days between the first date of first documentation of objective tumor response (CR or PR) and the date of tumor progression or death due to any cause whichever occurred first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response (OR) - Phase 1 and 2</measure>
    <time_frame>Baseline, on treatment every 8 weeks until progression and at the end of treatment (up to 12 months)</time_frame>
    <description>Number of patients who achieved a CR or PR as per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year Overall Survival (1yr-OS) - Phase 2</measure>
    <time_frame>From the date of randomization, every 3 months until death up 12 months.</time_frame>
    <description>Number of alive patients at 1 year from the date of randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year Overall Survival (2yr-OS) - Phase 2</measure>
    <time_frame>From the date of randomization, every 3 months until death up to 24 months.</time_frame>
    <description>Number of alive patients at 2 years from the date of randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) - Phase 2</measure>
    <time_frame>Baseline, on treatment every 8 weeks and at the end of treatment up to 12 months.</time_frame>
    <description>PFS is defined as the difference in days between the first date that criteria for progression was met or the patient died due to any cause and the date of randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory-Short Form (BPI-sf) - Phase 2</measure>
    <time_frame>Baseline, on Day 1 of each cycle and at the end of treatment up to 12 months.</time_frame>
    <description>BPI-sf is an 11-item self-report questionnaire that is designed to assess the severity and impact of pain on daily functions. BPI-sf are 4 questions that assess pain intensity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). Each question is answered on a scale ranging from 0 to 10; '0=No pain and 10=Pain as bad as you can imagine'. Measure can be scored by item, with lower scores being indicative of less pain or pain interference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc interval - Phase 1 and 2</measure>
    <time_frame>Baseline, Cycle 1 Days 1 or 3 and 22. From cycle &gt;1 on Day 1 and at the end of treatment up to 12 months.</time_frame>
    <description>QTc duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) - Phase 1</measure>
    <time_frame>Cycle 1: Day 3 ( pre-dose, 0.5,1,4 hrs after the morning dose), Days 15 &amp; 22 (pre-dose, 0.5, 1,2,4, 8 hrs after the morning dose). Day 1 of Cycles 2 &amp; 3 (pre-dose and 1 hr after the morning dose).</time_frame>
    <description>For PF-03084014</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) - Phase 1</measure>
    <time_frame>Cycle 1: Day 3 ( pre-dose, 0.5,1,4 hrs after the morning dose), Days 15 &amp; 22 (pre-dose, 0.5, 1,2,4, 8 hrs after the morning dose). Day 1 of Cycles 2 &amp; 3 (pre-dose and 1 hr after the morning dose).</time_frame>
    <description>For PF-03084014</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration versus time curve (AUC) - Phase 1</measure>
    <time_frame>Cycle 1: Day 3 ( pre-dose, 0.5,1,4 hrs after the morning dose), Days 15 &amp; 22 (pre-dose, 0.5, 1,2,4, 8 hrs after the morning dose). Day 1 of Cycles 2 &amp; 3 (pre-dose and 1 hr after the morning dose).</time_frame>
    <description>For PF-03084014</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) - Phase 1</measure>
    <time_frame>Cycle 1 Days 1 &amp; 15 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 24 &amp; 48 hrs after the start of infusion.</time_frame>
    <description>For nab-paclitaxel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) - Phase 1</measure>
    <time_frame>Cycle 1 Days 1 &amp; 15 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 24 &amp; 48 hrs after the start of infusion.</time_frame>
    <description>For nab-paclitaxel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration versus time curve (AUC) - Phase 1</measure>
    <time_frame>Cycle 1 Days 1 &amp; 15 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 24 &amp; 48 hrs after the start of infusion.</time_frame>
    <description>For nab-paclitaxel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) - Phase 1</measure>
    <time_frame>Cycle 1 Days 1 &amp; 15 ( pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3 hrs after the start of infusion.</time_frame>
    <description>For gemcitabine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) - Phase 1</measure>
    <time_frame>Cycle 1 Days 1 &amp; 15 ( pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3 hrs after the start of infusion.</time_frame>
    <description>For gemcitabine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration versus time curve (AUC) - Phase 1</measure>
    <time_frame>Cycle 1 Days 1 &amp; 15 ( pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3 hrs after the start of infusion.</time_frame>
    <description>For gemcitabine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Quality of Life Questionnaire (EQ-5D) - Phase 2</measure>
    <time_frame>Baseline, on Day 1 of each cycle and at the end of treatment up to 12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire (EORTC-QLQ-C30) - Phase 2</measure>
    <time_frame>Baseline, on Day 1 of each cycle and at the end of treatment up to 12 months.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Metastatic Cancer Pancreas</condition>
  <arm_group>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-03084014 in combination with gemcitabine and nab-paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-03084014 in combination with gemcitabine and nab-paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine plus nab-Paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03084014</intervention_name>
    <description>Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Doses: 100 -150 mg BID</description>
    <arm_group_label>Phase 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.</description>
    <arm_group_label>Phase 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.</description>
    <arm_group_label>Phase 1</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03084014</intervention_name>
    <description>Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Phase 2 dose will be the recommended phase 2 dose defined in phase 1.</description>
    <arm_group_label>Phase 2 Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.</description>
    <arm_group_label>Phase 2 Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.</description>
    <arm_group_label>Phase 2 Arm A</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.</description>
    <arm_group_label>Phase 2 Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.</description>
    <arm_group_label>Phase 2 Arm B</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically diagnosis of metastatic ductal adenocarcinoma of the
             pancreas.

          -  No prior radiotherapy, surgery chemotherapy or investigational therapy for metastatic
             disease. Prior adjuvant therapy with 5-FU or gemcitabine (Â± gemcitabine post
             radiation) administered as radiosensitizer allowed, provided at least 6 months have
             elapsed between the last dose and study registration

          -  Tumor tissue available (Archival 6 months old or de novo biopsy)

          -  Measurable disease as per RECIST 1.1

          -  Performance Status (ECOG) 0 or 1

        Exclusion Criteria:

          -  Symptomatic brain metastases requiring steroids

          -  Prior therapy with gamma secretase inhibitors or other Notch pathway inhibitor

          -  Major surgery within 4 weeks of registration in the current study

          -  Known hypersensitivity to gemcitabine or nab-paclitaxel or any of the excipients

          -  Current or anticipated need for food or drugs that are strong/moderate CYP3A4
             inhibitors or inducers

          -  Diagnosis of any second malignancy within 3 years prior to registration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anschutz Inpatient Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drug Shipment: Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver, CTO (CTRC)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Investigational Drug Pharmacy</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8641019</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 7, 2015</lastchanged_date>
  <firstreceived_date>April 2, 2014</firstreceived_date>
  <firstreceived_results_disposition_date>December 7, 2015</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
